In vitro and in vivo activity of ciprofloxacin/ fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates

6Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Objective: Ciprofloxacin resistance (CIPR) for Shigella isolates is becoming more prevalent. This study systematically investigated the antibacterial activity of ciprofloxacin (CIP)/ fosfomycin (FOS) combination in vitro and in vivo against CIPR S. flexneri isolates. Method: Eighty CIPR S. flexneri isolates were selected for synergy studies by the microtiter plate checkerboard assay. Two S. flexneri isolates (GN120471, CIPRFOSR; GN120454, CIPRFOSS) were used to investigate the efficacy of the CIP/FOS combination by the time-kill methodology. Clinically relevant concentrations (CIP, 0.5, 1, or 2.5 μg/mL; FOS, 30, 150, or 300 μg/mL) were combined, and the colony counts were conducted at 3, 5, 8, and 24 hours. The in vivo activity of the CIP/FOS combination was assessed using a Galleria mellonella larvae model. Results: In checkerboard assays, 31 strains (38.75%) showed synergy for the CIP/FOS combination. For the isolate GN120471, monotherapy with CIP or FOS at all concentrations produced little or no bacterial killing, while the CIP/FOS combination produced enhanced bacterial killing with FOS concentrations of 150 and 300 μg/mL, especially when combined with CIP at 2.5 μg/mL. For the isolate GN120454, the CIP/FOS combination at all concentrations produced more rapid and extensive killing (up to 5log10 colony forming units (CFU)/ mL with many combinations) than with either antibiotic alone. Mortality at 96 hours was around 80% at approximately 104 CFU/larva for GN120471 and GN120454. When CIP at 2.5 μg/mL was combined with FOS at 150 μg/mL for the bactericidal activity in vivo, the survival rates for CIP/FOS combination against GN120471-infected and GN120454-infected larvae were significantly higher than that of CIP (68.75% vs 25%, P=0.013; 81.25% vs 37.5%, P=0.012, respectively). Conclusion: Against CIPR S. flexneri isolates, the CIP/FOS combination induced synergy, and increased bacterial killing in vitro and in a simple invertebrate model of infection.

Cite

CITATION STYLE

APA

Liu, Y., Li, H., Zhang, Y., Ye, Y., Gao, Y., & Li, J. (2019). In vitro and in vivo activity of ciprofloxacin/ fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates. Infection and Drug Resistance, 12, 1619–1628. https://doi.org/10.2147/IDR.S208071

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free